Compare Archer-Daniels-Midland Co (ADM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Novo Nordisk A/S — how do they compare? Archer-Daniels-Midland Co trades at $80.09 (market cap $38.78B), while Novo Nordisk A/S trades at $46.19 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.4× Archer-Daniels-Midland Co's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ADM | NVO | |
|---|---|---|
Market Cap | $38.78B | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $63.98 |
52-Week Low | $56.00 | $35.29 |
Enterprise Value | $47.03B | $222.55B |
Dividend Yield | 2.59% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.41, down 1.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.84, exceeding expectations, and raised its full-year outlook, driven by biofuels and crushing margins. Valuation ratios like P/E of 21.98 and P/S of 0.48 suggest reasonable pricing relative to peers. Cash flow improved in 2025 with net cash flow of $1.58 billion.
The outlook is positive with analyst consensus price target of $88.00, implying upside. Key opportunities include growth in AgTech and biofuels, while risks involve execution challenges and volatile commodity markets. The stock offers a dividend yield supported by consistent payments, but investors should monitor margin pressures from input costs.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
